152 related articles for article (PubMed ID: 15623657)
1. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma.
Cooper C; Liu GY; Niu YL; Santos S; Murphy LC; Watson PH
Clin Cancer Res; 2004 Dec; 10(24):8720-7. PubMed ID: 15623657
[TBL] [Abstract][Full Text] [Related]
2. [Hypoxia induces down-regulation of estrogen receptor alpha in human breast cancer].
Liu GY; Shen KW; Shao ZM; Shen ZZ
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):664-8. PubMed ID: 15777504
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
[TBL] [Abstract][Full Text] [Related]
4. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
Birle DC; Hedley DW
Cancer Res; 2007 Feb; 67(4):1735-43. PubMed ID: 17308115
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells.
Stoner M; Saville B; Wormke M; Dean D; Burghardt R; Safe S
Mol Endocrinol; 2002 Oct; 16(10):2231-42. PubMed ID: 12351689
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
7. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells.
Rafajová M; Zatovicová M; Kettmann R; Pastorek J; Pastoreková S
Int J Oncol; 2004 Apr; 24(4):995-1004. PubMed ID: 15010840
[TBL] [Abstract][Full Text] [Related]
8. [Effect of bortezomib on VEGF gene expression of endothelial cell line HMEC-1 and its possible mechanisms].
Xue LX; Jiang M; Xie LQ; Ruan CG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):744-8. PubMed ID: 20561442
[TBL] [Abstract][Full Text] [Related]
9. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
Wykoff CC; Beasley N; Watson PH; Campo L; Chia SK; English R; Pastorek J; Sly WS; Ratcliffe P; Harris AL
Am J Pathol; 2001 Mar; 158(3):1011-9. PubMed ID: 11238049
[TBL] [Abstract][Full Text] [Related]
10. Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells.
Xu H; Ju D; Jarois T; Xie Y
Breast Cancer Res Treat; 2008 Jan; 107(2):267-74. PubMed ID: 17431761
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B.
Prenzel T; Begus-Nahrmann Y; Kramer F; Hennion M; Hsu C; Gorsler T; Hintermair C; Eick D; Kremmer E; Simons M; Beissbarth T; Johnsen SA
Cancer Res; 2011 Sep; 71(17):5739-53. PubMed ID: 21862633
[TBL] [Abstract][Full Text] [Related]
12. Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro.
Said HM; Polat B; Staab A; Hagemann C; Stein S; Flentje M; Theobald M; Katzer A; Vordermark D
Oncol Rep; 2008 Aug; 20(2):413-9. PubMed ID: 18636206
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
Mackay H; Hedley D; Major P; Townsley C; Mackenzie M; Vincent M; Degendorfer P; Tsao MS; Nicklee T; Birle D; Wright J; Siu L; Moore M; Oza A
Clin Cancer Res; 2005 Aug; 11(15):5526-33. PubMed ID: 16061869
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells.
Periyasamy-Thandavan S; Jackson WH; Samaddar JS; Erickson B; Barrett JR; Raney L; Gopal E; Ganapathy V; Hill WD; Bhalla KN; Schoenlein PV
Autophagy; 2010 Jan; 6(1):19-35. PubMed ID: 20110775
[TBL] [Abstract][Full Text] [Related]
15. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis.
Colpaert CG; Vermeulen PB; Fox SB; Harris AL; Dirix LY; Van Marck EA
Breast Cancer Res Treat; 2003 Sep; 81(2):137-47. PubMed ID: 14572156
[TBL] [Abstract][Full Text] [Related]
16. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.
Sisinni L; Maddalena F; Lettini G; Condelli V; Matassa DS; Esposito F; Landriscina M
Int J Oncol; 2014 Feb; 44(2):573-82. PubMed ID: 24297638
[TBL] [Abstract][Full Text] [Related]
17. Necrosis and hypoxia in invasive breast carcinoma.
Tomes L; Emberley E; Niu Y; Troup S; Pastorek J; Strange K; Harris A; Watson PH
Breast Cancer Res Treat; 2003 Sep; 81(1):61-9. PubMed ID: 14531498
[TBL] [Abstract][Full Text] [Related]
18. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome.
Trastour C; Benizri E; Ettore F; Ramaioli A; Chamorey E; Pouysségur J; Berra E
Int J Cancer; 2007 Apr; 120(7):1451-8. PubMed ID: 17245699
[TBL] [Abstract][Full Text] [Related]
19. Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells.
Maynadier M; Shi J; Vaillant O; Gary-Bobo M; Basile I; Gleizes M; Cathiard AM; Wah JL; Sheikh MS; Garcia M
Mol Cancer Res; 2012 Nov; 10(11):1473-81. PubMed ID: 22964432
[TBL] [Abstract][Full Text] [Related]
20. Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
Padró M; Louie RJ; Lananna BV; Krieg AJ; Timmerman LA; Chan DA
BMC Cancer; 2017 Mar; 17(1):203. PubMed ID: 28320353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
